Sport video provider Whistle Sports Network has secured $28m in series B funding from Tengelmann subsidiary Emil, Liberty Global and Sky.
Author: Thierry Heles
CoLucid clears way for $37m series C
CoLucid Pharmaceuticals, which is working on a treatment for migraines, has secured backing from investors including Novo to take its total financing above the $100m mark.
Twitter calls up ZipDial
Social network Twitter has reportedly entered talks to acquire the Times Internet-backed mobile marketing startup for up to $40m.
Ionic secures $40m for series C
US-based distributed data security platform Ionic Security raised $40.1m yesterday in a series C round featuring Google Ventures, the corporate venturing arm of internet company Google. Meritech Capital Partners led the round, which included investments by Kleiner Perkins Caufield & Byers (KPCB), Tech Operators and Jafco Ventures. Ionic has now raised about $78m in total.… Continue reading Ionic secures $40m for series C
Kit Check tracks $12m
The medication tracking software provider raised the money in a Kaiser Permanente-led series B round that also included Rex Healthcare.
Ele.me eats up big investment
Dianping-backed food delivery startup Ele.me has raised new funding in a round reportedly led by a China-based technology provider.
Fosun dines on Amerigen stake
Fosun Pharma will invest $35m in the generic pharmaceuticals producer, which will invest the cash in developing its product pipeline.
MongoDB adds $80m to its database
The Salesforce.com, Intel, In-Q-Tel and Red Hat-backed big data technology company has now secured a total of $311m in funding.
Novartis and Qualcomm form joint investment unit
The two companies have set up a joint investment company which will invest a total of up to $100m in digital medicine startups.
Eli Lilly promotes Darren Carroll
Carroll has been promoted from his position as vice president at Lilly Ventures to senior vice president.
AveXis shows spine for $10m series C
Roche co-led a round for AveXis that will help fund development of its spinal muscular atrophy treatment.
Novo returns for Orphazyme series B
Orphazyme has secured $24m in a Novo-backed round that will fund a clinical trial for its lead drug candidate, a treatment for a rare cholesterol-caused disease.
Welltok manages its health with $37m
New investors including Hearst Health Ventures and Catholic Health Initiatives have joined the company’s series D round, taking its overall funding to almost $83m.
Invitae to test public markets
The Genomic Health-backed genetic testing company intends to raise $86m from an initial public offering on the New York Stock Exchange.